The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
The decision is based on the phase 3 DESTINY-Breast11 trial
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
Doctors at the hospital highlighted that robotic-assisted surgery enhances precision through superior 3D visualisation and improved instrument flexibility
Subscribe To Our Newsletter & Stay Updated
